Key result
Positron emission tomography (PET) and PET/CT imaging play an established and expanding role in evaluating cardiomyopathy and monitoring cardiovascular stem cell therapy.
PET imaging is a valuable noninvasive tool for evaluating various cardiomyopathies and monitoring emerging treatments like stem cell therapy.
PET may aid cardiomyopathy evaluation; leaves open prospective trials for stem cell monitoring.
Congestive heart failure accounts for tremendous morbidity and mortality worldwide. There are numerous causes of cardiomyopathy, the most common of which is coronary artery disease. Positron emission tomography (PET) has an established and expanding role in the evaluation of patients with cardiomyopathy. The specific application of PET to hypertrophic cardiomyopathy, cardiac sarcoidosis, and diabetic cardiomyopathy has been studied extensively and promises to be a useful tool for managing these patients. Furthermore, evaluating the efficacy of standard treatments for congestive heart failure is important as health care costs continue to rise. Recently, there have been significant developments in the field of cardiovascular stem cell research. Familiarity with the mechanisms by which stem cells benefit patients with cardiovascular disease is the key to understanding these advances. Molecular imaging techniques including PET/CT imaging play an important role in monitoring stem cell therapy in both animals and humans. These noninvasive imaging techniques will be highlighted in this paper.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2011) conducted a review in Cardiomyopathy and congestive heart failure. Positron emission tomography (PET) was evaluated. Positron emission tomography (PET) and PET/CT imaging play an established and expanding role in evaluating cardiomyopathy and monitoring cardiovascular stem cell therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: